Kee KM - Search Results

1

Reciprocal interactions among Cobll1, PACSIN2, and SH3BP1 regulate drug resistance in chronic myeloid leukemia.

Park K, Yoo HS, Oh CK, Lee JR, Chung HJ, Kim HN, Kim SH, Kee KM, Kim TY, Kim M, Kim BG, Ra JS, Myung K, Kim H, Han SH, Seo MD, Lee Y, Kim DW. Park K, et al. Among authors: kee km. Cancer Med. 2022 Nov;11(21):4005-4020. doi: 10.1002/cam4.4727. Epub 2022 Mar 30. Cancer Med. 2022. PMID: 35352878 Free PMC article.

2

Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy.

Lee SE, Choi SY, Kim SH, Song HY, Yoo HL, Lee MY, Hwang HJ, Kang KH, Kee KM, Jang EJ, Kim DW. Lee SE, et al. Among authors: kee km. Leuk Lymphoma. 2018 Jan;59(1):105-113. doi: 10.1080/10428194.2017.1320711. Epub 2017 May 25. Leuk Lymphoma. 2018. PMID: 28540759

3

BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors.

Song HY, Noh H, Choi SY, Lee SE, Kim SH, Kee KM, Yoo HL, Lee MY, Kang KH, Suh JH, Yang SY, Jang EJ, Lee JI, Kim DW. Song HY, et al. Among authors: kee km. Cancer Med. 2018 Oct;7(10):5107-5117. doi: 10.1002/cam4.1753. Epub 2018 Aug 31. Cancer Med. 2018. PMID: 30171671 Free PMC article.

4

Compound mutations involving T315I and P-loop mutations are the major components of multiple mutations detected in tyrosine kinase inhibitor resistant chronic myeloid leukemia.

Kang KH, Kim SH, Choi SY, Yoo HL, Lee MY, Song HY, Kee KM, Suh JH, Yang SY, Jang EJ, Lee SE, Kim DW. Kang KH, et al. Among authors: kee km. Leuk Res. 2019 Jan;76:87-93. doi: 10.1016/j.leukres.2018.10.019. Epub 2018 Nov 27. Leuk Res. 2019. PMID: 30503643

5

Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia.

Shin H, Choi SY, Kee KM, Kim SH, Yang SY, Jung SY, Noh H, Zang DY, Kim DW, Lee JI. Shin H, et al. Among authors: kee km. Int J Hematol. 2020 Mar;111(3):417-426. doi: 10.1007/s12185-019-02805-9. Epub 2019 Dec 20. Int J Hematol. 2020. PMID: 31863342

6

Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia.

Kee KM, Kim SH, Yang SY, Shin JU, Nam YW, Jang EJ, Kim HT, Lee SM, Park SH, Kim DW. Kee KM, et al. Leuk Res. 2022 Jan;112:106754. doi: 10.1016/j.leukres.2021.106754. Epub 2021 Nov 22. Leuk Res. 2022. PMID: 34906861

7

Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia.

Shin JE, Kim SH, Kong M, Kim HR, Yoon S, Kee KM, Kim JA, Kim DH, Park SY, Park JH, Kim H, No KT, Lee HW, Gee HY, Hong S, Guan KL, Roe JS, Lee H, Kim DW, Park HW. Shin JE, et al. Among authors: kee km. Mol Cancer. 2023 Nov 6;22(1):177. doi: 10.1186/s12943-023-01837-4. Mol Cancer. 2023. PMID: 37932786 Free PMC article.

8

Hepatitis B virus-related hepatocellular carcinoma has superior overall survival compared with other etiologies.

Yen YH, Kee KM, Hu TH, Tsai MC, Kuo YH, Li WF, Liu YW, Wang CC, Lin CY. Yen YH, et al. Among authors: kee km. PLoS One. 2024 Mar 15;19(3):e0290523. doi: 10.1371/journal.pone.0290523. eCollection 2024. PLoS One. 2024. PMID: 38489301 Free PMC article.

9

Modeling the influence of attitudes, trust, and beliefs on endoscopists' acceptance of artificial intelligence applications in medical practice.

Schulz PJ, Lwin MO, Kee KM, Goh WWB, Lam TYT, Sung JJY. Schulz PJ, et al. Among authors: kee km. Front Public Health. 2023 Nov 28;11:1301563. doi: 10.3389/fpubh.2023.1301563. eCollection 2023. Front Public Health. 2023. PMID: 38089040 Free PMC article.

10

Nomogram to Predict the Long-Term Overall Survival of Early-Stage Hepatocellular Carcinoma after Radiofrequency Ablation.

Kuo YH, Huang TH, Yen YH, Lu SN, Wang JH, Hung CH, Chen CH, Tsai MC, Kee KM. Kuo YH, et al. Among authors: kee km. Cancers (Basel). 2023 Jun 12;15(12):3156. doi: 10.3390/cancers15123156. Cancers (Basel). 2023. PMID: 37370766 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

106 results

Search Page